Mind Pump: Raw Fitness Truth 2802: The State of the Hormone & Peptide Industry w/ Vita Bella Founder Phil Vella
13 snips
Feb 26, 2026 Phil Vella, founder and CEO of Vita Bella Health and serial entrepreneur from tech, shares how he built a membership-driven hormone and peptide company. He calls out the gray-market risks and quality failures. He explains Vita Bella’s membership model, thoughts on GLP-1 regulation and combined care, and the future collision between pharma, compounding, and consumer demand.
AI Snips
Chapters
Transcript
Episode notes
Why Phil Left Tech To Build Vita Bella
- Phil Vella left a high-paying tech role to become a single dad and founded Vita Bella after seeing overpriced hormone care during his spinal fusion recovery.
- He discovered a 10x markup on meds (charged $22k vs $2.2k) and built a membership medical service to deliver affordable, doctor-led peptide and hormone care.
Membership Model Makes Peptide Care Scalable
- Phil built Vita Bella like a software company using a membership SaaS model to stabilize revenue and control operating expenses.
- The membership includes quarterly doctor visits and access to many treatment categories, letting predictable revenue fund lower med prices and better service.
Avoid Research Grade Peptides Without Labs
- Avoid buying research-grade peptides without medical guidance because many sellers mislabel, have no QC, and patients present with dangerous lab abnormalities.
- Phil's company tested samples that returned unknown contents or wildly variable purity (e.g., NAD 23%–120%).